Compare FNKO & PROF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FNKO | PROF |
|---|---|---|
| Founded | 2017 | N/A |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Recreational Games/Products/Toys | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 301.5M | 247.5M |
| IPO Year | 2017 | 2017 |
| Metric | FNKO | PROF |
|---|---|---|
| Price | $5.55 | $7.05 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | $6.00 | ★ $12.00 |
| AVG Volume (30 Days) | ★ 571.0K | 75.9K |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 25.89 |
| EPS | N/A | ★ 0.19 |
| Revenue | ★ $908,209,000.00 | $16,098,000.00 |
| Revenue This Year | $4.42 | $92.40 |
| Revenue Next Year | $6.50 | $64.10 |
| P/E Ratio | ★ N/A | $37.42 |
| Revenue Growth | N/A | ★ 50.73 |
| 52 Week Low | $2.22 | $3.92 |
| 52 Week High | $6.09 | $8.95 |
| Indicator | FNKO | PROF |
|---|---|---|
| Relative Strength Index (RSI) | 54.16 | 49.51 |
| Support Level | $5.06 | $6.43 |
| Resistance Level | $5.87 | $7.06 |
| Average True Range (ATR) | 0.29 | 0.37 |
| MACD | -0.02 | 0.03 |
| Stochastic Oscillator | 53.25 | 36.51 |
Funko Inc is an USA based pop culture consumer products company. It creates whimsical, fun, and different products that enable the customer to express their affinity for their favorite through the movie, TV show, video game, musician, or sports team. The company's current products are principally figures, fashion accessories, apparel, plush products, accessories, homewares, and NFTs. The company sells its products through a diverse network of retail customers across multiple retail channels, including specialty retailers, mass-market retailers, and e-commerce sites. The company generates the majority of its revenue from the core collectibles products.
Profound Medical Corp is a commercial-stage medical device company focused on the development and marketing of AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue. The company's flagship product, the TULSA-PRO system, combines real-time MRI, robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to ablate whole gland or physician defined region of malignant or benign prostate tissue. Its platform technologies combine imaging, robotic control, and ultrasound-based thermal ablation for the treatment of prostate conditions. The company generates revenue through the sale of capital equipment and recurring sales of single-use devices and related services used in patient treatments.